0000000000722938

AUTHOR

Robert Kiełbasiński

showing 2 related works from this author

Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer.

2019

Background:Many experimental studies have demonstrated the importance of COX-2 in the tumor angiogenesis. Inducible iNOS is responsible for a high and stable level of nitric oxide and is expressed in response to pro-inflammatory factors.Objective:The aim of this study was to evaluate the expression of COX-2 and iNOS at the protein level and to assess their potential prognostic significance in patients with endometrial cancer.Methods:The study group consisted of 45 women with endometrial cancer divided according to the degree of histological differentiation i.e. G1, 17; G2, 15; G3, 13. The control group consisted of 15 women without neoplastic changes. The expression of studied proteins was …

0301 basic medicineTumor angiogenesisAngiogenesisPharmaceutical ScienceNitric Oxide Synthase Type IINitric oxideAndrologyangiogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndometrial cancerMedicineHumansIn patientAgedmolecular markerbiologybusiness.industryEndometrial cancerProtein levelCOX-2Middle Agedneoplastic changesmedicine.diseasePrognosisReaction productEndometrial NeoplasmsiNOS030104 developmental biologychemistryPolyclonal antibodiesCyclooxygenase 2030220 oncology & carcinogenesisbiology.proteinFemaleNeoplasm GradingbusinessBiotechnologyCurrent pharmaceutical biotechnology
researchProduct

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer

2019

Background: VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated. Objective: The aim of the study was to evaluate changes in VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 expression in endometrial cancer depending on its grade and to determine the VEGFR-1 to VEGFR-2 concentration ratio. Methods: The study group consisted of 45 patients diagnosed with endometrial cancer (G1, 17; G2, 15; G3, 13). The control group included 15 patients. VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 expression was assessed using the immunohistochemical method. Statistical analysis was carried out…

0301 basic medicineOncologyTumor angiogenesisVascular Endothelial Growth Factor Amedicine.medical_specialtyVascular Endothelial Growth Factor BVEGF-A/BAngiogenesisPharmaceutical ScienceArticle03 medical and health sciencesangiogenesis0302 clinical medicineInternal medicineMedicineHumansAdenomyosisRNA MessengerVascular Endothelial Growth Factor Receptor-1integumentary systemNeovascularization Pathologicbusiness.industryEndometrial cancerCancerVEGFR-1/2tumor angiogenesismedicine.diseasePrognosisImmunohistochemistryVascular Endothelial Growth Factor Receptor-2Endometrial Neoplasms030104 developmental biologymedicine.anatomical_structureadenomyosis030220 oncology & carcinogenesisCase-Control Studiesembryonic structuresendometrial cancercardiovascular systemImmunohistochemistryFemaleAnalysis of varianceNeoplasm GradingbusinessBiotechnologyBlood vesselCurrent Pharmaceutical Biotechnology
researchProduct